Ashland Facility Achieves EXCiPACT Certification
Ashland Chemical’s Calvert City, KY, facility is the first in the US to receive EXCiPACT certification for GMPs of pharmaceutical excipients.
Ashland announced on Feb. 11, 2015 that its manufacturing plant in Calvert City, KY, is first US excipient facility to receive EXCiPACT certification for good manufacturing practice. The certification covers the manufacturing, testing, and packaging of polyvinylpyrrolidone and polyvinylpolypyrrolidone used as pharmaceutical excipients.
In a press statement, Ashland reports a goal of having all of its global pharmaceutical excipient facilities certified by 2017.
The EXCiPACT Certification Scheme is a third-party international certification scheme for manufacturers, suppliers, and distributors of pharmaceutical excipients.
Source: Ashland
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
